Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu
April 01 2021 - 5:30PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading
point-of-care diagnostics company focused on infectious diseases,
today announced the commercial launch of an FDA Emergency Use
Authorization-approved, in-licensed rapid point-of-care
COVID-19/Flu A&B test, for use in decentralized and traditional
testing settings. Product inventory is on-hand and immediately
available for shipment to customers across the United States.
The rapid immunoassay test is approved for use in laboratories
with a CLIA waiver license, produces results in 15 minutes and
requires no instrumentation. The test simultaneously differentiates
SARS-CoV-2 antigens and influenza Type A and Type B infections from
a single swab.
“As COVID-19 converges with the flu, it is critical
for physicians to be able to quickly differentiate between these
viruses at the point-of-care, which present with nearly identical
symptoms, in order to take appropriate clinical actions and
maximize efficient use of healthcare resources,” said Charles Caso,
Vice President of Sales and Marketing for Chembio. “Based on recent
research, we expect that the spread of COVID-19 will eventually
transition from a pandemic to an endemic state, with the virus
surviving among the population at a lower incidence. In this
scenario, coupled with the return to normalcy in society, we see
COVID-19 testing remaining a crucial and integral component of
broader respiratory testing.”
About Chembio DiagnosticsChembio
is a leading point-of-care diagnostics company focused on detecting
and diagnosing infectious diseases, including COVID-19, sexually
transmitted disease, and fever and tropical disease. Coupled with
Chembio’s extensive scientific expertise, its novel DPP technology
offers broad market applications beyond infectious disease.
Chembio’s products are sold globally, directly and through
distributors, to hospitals and clinics, physician offices, clinical
laboratories, public health organizations, government agencies, and
consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark, and the Chembio logo is
Chembio’s trademark. For convenience, these trademarks appear in
this release without ® or ™ symbols, but that practice does not
mean that Chembio will not assert, to the fullest extent under
applicable law, its rights to the trademark.
Contact: Brian JohnstonGilmartin
Group631-807-1986investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2023 to Apr 2024